These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 32988825)

  • 21. A practical laboratory method to determine ceftazidime-avibactam-aztreonam synergy in patients with New Delhi metallo-beta-lactamase (NDM)-producing Enterobacterales infection.
    Rawson TM; Brzeska-Trafny I; Maxfield R; Almeida M; Gilchrist M; Gonzalo X; Moore LS; Donaldson H; Davies F
    J Glob Antimicrob Resist; 2022 Jun; 29():558-562. PubMed ID: 35131508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing
    Bhatnagar A; Boyd S; Sabour S; Bodnar J; Nazarian E; Peinovich N; Wagner C; Craft B; Snippes Vagnone P; Simpson J; Stone VN; Therrien M; Bateman A; Lower D; Huang JY; Gumbis S; Lonsway D; Lutgring JD; Karlsson M; Brown AC
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0048621. PubMed ID: 34060895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae.
    Maraki S; Mavromanolaki VE; Moraitis P; Stafylaki D; Kasimati A; Magkafouraki E; Scoulica E
    Eur J Clin Microbiol Infect Dis; 2021 Aug; 40(8):1755-1759. PubMed ID: 33595756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.
    Papp-Wallace KM; Winkler ML; Gatta JA; Taracila MA; Chilakala S; Xu Y; Johnson JK; Bonomo RA
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4290-7. PubMed ID: 24820081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-vitro susceptibility testing methods for the combination of ceftazidime-avibactam with aztreonam in metallobeta-lactamase producing organisms: Role of combination drugs in antibiotic resistance era.
    Sreenivasan P; Sharma B; Kaur S; Rana S; Biswal M; Ray P; Angrup A
    J Antibiot (Tokyo); 2022 Aug; 75(8):454-462. PubMed ID: 35715617
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Cienfuegos-Gallet AV; Shashkina E; Chu T; Zhu Z; Wang B; Kreiswirth BN; Chen L
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0134623. PubMed ID: 38426743
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
    [No Abstract]   [Full Text] [Related]  

  • 28. Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.
    Mendes RE; Doyle TB; Streit JM; Arhin FF; Sader HS; Castanheira M
    J Antimicrob Chemother; 2021 Oct; 76(11):2833-2838. PubMed ID: 34436603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
    Papp-Wallace KM; Bajaksouzian S; Abdelhamed AM; Foster AN; Winkler ML; Gatta JA; Nichols WW; Testa R; Bonomo RA; Jacobs MR
    Diagn Microbiol Infect Dis; 2015 May; 82(1):65-9. PubMed ID: 25737290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hijacking a small plasmid to confer high-level resistance to aztreonam-avibactam and ceftazidime-avibactam.
    Ma K; Feng Y; McNally A; Zong Z
    Int J Antimicrob Agents; 2023 Nov; 62(5):106985. PubMed ID: 37769749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of testing methods assessing the in vitro efficacy of the combination of aztreonam with avibactam on multidrug-resistant Gram-negative bacilli.
    Deckers C; Bélik F; Denis O; Bogaerts P; Montesinos I; Berhin C; Bouchahrouf W; Hoebeke M; Evrard S; Gilliard N; Okur M; Huang TD
    Ann Clin Microbiol Antimicrob; 2024 May; 23(1):47. PubMed ID: 38796461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of cefepime/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3.
    Bhagwat SS; Hariharan P; Joshi PR; Palwe SR; Shrivastava R; Patel MV; Devanga Ragupathi NK; Bakthavatchalam YD; Ramesh MS; Soman R; Veeraraghavan B
    J Antimicrob Chemother; 2020 Dec; 75(12):3563-3567. PubMed ID: 32772098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine- and New Delhi metallo-β-lactamases.
    Feng K; Jia N; Zhu P; Sy S; Liu Y; Dong D; Zhu S; Zhang J; Liu Y; Martins FS; Gong H; Lv Z; Yu M; Sy SKB; Zhu Y
    J Antimicrob Chemother; 2021 Oct; 76(11):2875-2883. PubMed ID: 34383928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam.
    Mojica MF; Papp-Wallace KM; Taracila MA; Barnes MD; Rutter JD; Jacobs MR; LiPuma JJ; Walsh TJ; Vila AJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784669
    [No Abstract]   [Full Text] [Related]  

  • 35. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
    Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
    Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to aztreonam-avibactam among clinical isolates of Escherichia coli is primarily mediated by altered penicillin-binding protein 3 and impermeability.
    Tellapragada C; Razavi M; Peris PS; Jonsson P; Vondracek M; Giske CG
    Int J Antimicrob Agents; 2024 Sep; 64(3):107256. PubMed ID: 38925228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of aztreonam/avibactam against a global collection of Klebsiella pneumoniae collected from defined culture sources in 2016 and 2017.
    Esposito S; Stone GG; Papaparaskevas J
    J Glob Antimicrob Resist; 2021 Mar; 24():14-22. PubMed ID: 32841721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance to aztreonam-avibactam due to CTX-M-15 in the presence of penicillin-binding protein 3 with extra amino acids in
    Ma K; Zong Z
    Front Microbiol; 2022; 13():1047109. PubMed ID: 36406430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent Emergence of Aztreonam-Avibactam Resistance in NDM and OXA-48 Carbapenemase-Producing Escherichia coli in Germany.
    Nordmann P; Yao Y; Falgenhauer L; Sadek M; Imirzalioglu C; Chakraborty T
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0109021. PubMed ID: 34424048
    [No Abstract]   [Full Text] [Related]  

  • 40. Novel Specific Metallo-β-Lactamase Inhibitor ANT2681 Restores Meropenem Activity to Clinically Effective Levels against NDM-Positive
    Zalacain M; Lozano C; Llanos A; Sprynski N; Valmont T; De Piano C; Davies D; Leiris S; Sable C; Ledoux A; Morrissey I; Lemonnier M; Everett M
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33820763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.